About Dr Ferguson

Dr Ferguson is a consultant Haematologist working at University Hospitals of North Midlands NHS trust. He is a specialist in treating patients with both malignant blood cancers (haemato-oncology) and those with general, benign blood disorders. He has a particular interest in treating patients with myeloid and lymphoid malignancies and bone marrow transplantation. Dr Ferguson is the lead clinician for Haematology and Acute Oncology within the trust. He is strongly patient focused and dedicated to delivering the best in patient care.

Dr Ferguson graduated with honours in Medicine from the University of Birmingham having previously attained a first class honours degree in Biomedical Science and a PhD in cancer research, with a focus on molecular biology, from Queen’s University, Belfast.

His haematology training was principally based at the Queen Elizabeth Hospital, Birmingham. During this time he was appointed as an academic clinical lecturer and aligned clinical commitments with clinical research. His areas for research were the delivery of early phase clinical trials, bone marrow transplantation and basic scientific research into the genetics of acute myeloid leukaemia which he undertook at Oxford University and the University of Birmingham. He is an author on a number of high impact clinical research publications and has received a national award for his research.

Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

C Craddock, D Slade, C De Santo, R Wheat, P Ferguson, A Hodgkinson, K Brock, J Cavenagh, W Ingram, M Dennis, R Malladi, S Siddique, F Mussai, C Yap. Journal of Clinical Oncology. 2019 Mar 1;37(7):580-588.

Outcome of Azacitidine Therapy in Acute Myeloid Leukemia is not Improved by Concurrent Vorinostat Therapy but is Predicted by a Diagnostic Molecular Signature. 

Craddock C, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai S, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P. Clinical Cancer Research. 2017 Nov 1;23 (21):6430-6440.

Allogeneic transplantation in primary refractory AML.

Ferguson P, Craddock C.

Bone Marrow Transplant. 2017 52:950-951.

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group. Haematologica. 2016 Nov;101(11):1351-1358. 

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Lynn Quek, Paul Ferguson, Marlen Metzner, Ikhlaaq Ahmed, Alison Kennedy, Catherine Garnett, Sally Jeffries, Claudia Walter, Kim Piechocki, Adele Timbs, Robert Danby, Manoj Raghavan, Andrew Peniket, Mike Griffiths, Andrew Bacon, Janice Ward, Keith Wheatley, Paresh Vyas, Charles Craddock. Blood Advances 2016 1:193-204.

Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Craddock C, Jilani N, Siddique S, Yap C, Khan J, Nagra S, Ward J, Ferguson P, Hazlewood P, Buka R, Vyas P, Goodyear O, Tholouli E, Crawley C, Russell N, Byrne J, Malladi R, Snowden J, Dennis M.

Biol Blood Marrow Transplant. 2016 Feb;22(2):385-90. 

Acquired isodisomy on chromosome 13 at diagnosis results in impaired overall survival in patients with FLT3-ITD mutant acute myeloid leukaemia.

Loke JC, Akiki S, Borrow J, Ewing J, Bokhari SW, Chandra D, Arrazi J, Hazlewood P, Arthur K, Walsh J, Membwange Y, Wandroo FA, Watts A, Borg A, Brock K, Ferguson P, Craddock C, Griffiths M, Raghavan M.

Leukemia. 2015 Dec;29(12):2404-7.

Complete genome sequence and comparative metabolic profiling of the prototypical enteroaggregative Escherichia coli strain 042

Chaudhuri RR, Sebaihia M, Hobman JL, Webber MA, Leyton DL, Goldberg MD, Cunningham A, Scott-Tucker A, Ferguson PR, Thomas C, Frankel G, Tang C, Dudley EG, Roberts IS, Rasko D, Pallen M, Parkhill J, Nataro J, Thomson NR, Henderson IR. PLoS One. 2010; 5(1): e8801.

The Escherichia coli biofilm-promoting protein Antigen-43 does not contribute to intestinal adhesion

Gracas de luna M, Scott-Tucker A, Ferguson PR, Moran N, Dudley E, Bobat S, Turner S, Nataro J, Owen P, Henderson IR. FEMS Microbiology Letters. 2008; 283 (2): 237-46.

Tyrosine Phosphorylation disrupts elongin interaction and accelerates SOCS3 degradation.

Haan S, Ferguson P, Sommer U, Hiermath M, McVicar DW, Heinrich PC, Johnson JA, Cacalano NA. Journal of Biological Chemistry. 2003; 278(34): 31972-9.

New interleukins: are there any more?

Gadina M, Ferguson PR, Johnston PG. Current Opinion in Infectious Disease. 2003; 16(3): 211-7.

The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and anti-folates.

Longley DB, Boyer J, Allen WL, Latif T, Ferguson PR, Maxwell PJ, McDermott U, Lynch M, Harkin DP, Johnston PG. Cancer Research. 2002; 62(9): 2644-9.

Suppressors of cytokine signalling (SOCS) regulate cytokine and growth factor responses in the immune system.

Ferguson PR and Johnston JA. Modern Aspects of Immunobiology. 2001; 2: 92-5.

Characterisation of a thymidylate synthase (TS)-inducible cell line: a model system for studying sensitivity to TS and non-TS targeted chemotherapies.

Longley DB, Ferguson PR, Boyer J, Latif T, Lynch M, Maxwell p, Harkin DP, Johnston PG. Clinical Cancer Research. 2001 ; 7(11): 3533-9.